Co-Authors
This is a "connection" page, showing publications co-authored by Jorge Duconge and Kyle Melin.
Connection Strength
2.229
-
Nu?ez-Medina H, Monero M, Torres LM, Leal E, Gonz?lez-Sep?lveda L, Mayor ?M, Renta JY, Gonz?lez-Garc?a ER, Gonz?lez A, Melin K, Scott SA, Rua?o G, Hernandez-Suarez DF, Duconge J. Implementing a Pharmacogenomic-driven Algorithm to Guide Antiplatelet Therapy among Caribbean Hispanics: A non-randomized prospective cohort study. medRxiv. 2023 Dec 06.
Score: 0.246
-
Yang G, Gonz?lez P, Moner? M, Carrasquillo K, Renta JY, Hernandez-Suarez DF, Botton MR, Melin K, Scott SA, Rua?o G, Roche-Lima A, Alarcon C, Ritchie MD, Perera MA, Duconge J. Discovery of Ancestry-specific Variants Associated with Clopidogrel Response among Caribbean Hispanics. medRxiv. 2023 Oct 02.
Score: 0.243
-
Duconge J, Santiago E, Hernandez-Suarez DF, Moner? M, L?pez-Reyes A, Rosario M, Renta JY, Gonz?lez P, Ileana Fern?ndez-Morales L, Antonio V?lez-Figueroa L, Arce O, Mar?n-Maldonado F, Nu?ez H, Melin K, Scott SA, Rua?o G. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci. 2021 11; 14(6):2254-2266.
Score: 0.210
-
Hernandez-Suarez DF, Melin K, Marin-Maldonado F, Nunez HJ, Gonzalez AF, Gonzalez-Sepulveda L, Rivas-Tumanyan S, Naik H, Rua?o G, Scott SA, Duconge J. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020 08 06; 10(8):e038936.
Score: 0.195
-
Segu? HA, Melin K, Qui?ones DS, Duconge J. A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. J Transl Genet Genom. 2020; 4:263-277.
Score: 0.195
-
Melin K, Moon JY, Qi Q, Hernandez-Suarez DF, Duconge J, Hua S, Gonzalez S, Zeng D, Kaplan RC. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. Pharmacogenomics. 2019 01; 20(2):75-83.
Score: 0.174
-
Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J. Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. Pharmgenomics Pers Med. 2018; 11:95-106.
Score: 0.168
-
Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nu?ez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6).
Score: 0.168
-
Hernandez-Suarez DF, N??ez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 03 28; 33(1):49-55.
Score: 0.166
-
Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241.
Score: 0.157
-
Hernandez-Suarez DF, Claudio-Campos K, Mirabal-Arroyo JE, Torres-Hern?ndez BA, L?pez-Candales A, Melin K, Duconge J. Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep. 2016 Oct-Dec; 4(4):2324709616682049.
Score: 0.151
-
Cede?o E, Cruz A, Cort?s J, Melin K, Roman L, Gonzalez A, Duconge J, Santiago D. Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series. Patient Prefer Adherence. 2022; 16:69-78.
Score: 0.054
-
Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194.
Score: 0.053
-
Santiago D, Mangas-Sanjuan V, Melin K, Duconge J, Zhao W, Venkataramanan R. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics. 2020 Dec 18; 12(12).
Score: 0.050